Background: Cardiopulmonary bypass induces a systemic inflammatory response that may contribute to clinical morbidity. Gaseous nitric oxide at relatively low concentrations may elicit peripheral anti-inflammatory effects in addition to a reduction of pulmonary resistances. We examined the effects of 20 ppm of inhaled nitric oxide administered for 8 hours during and after cardiopulmonary bypass.
Oxygen-derived free radicals are primarily involved in ischemia-reperfusion injury, maximally affecting the myocardium at the onset of reperfusion, after release of aortic clamp. 2 Reperfusion injury has a complex pathophysiology. It develops over a period of several hours and involves 2 distinct but related events, coined "the endothelial trigger" and "the neutrophil amplification" step. 3 One of the major early events leading to endothelial dysfunction is the loss of the release of nitric oxide (NO) by endothelial cells, which occurs within a few minutes of reestablishing flow. This finding has been demonstrated in both an intact animal subjected to myocardial ischemia-reperfusion and in an isolated perfused organ (the heart) subjected to reperfusion with a blood-free solution. 4 The endothelial dysfunction is followed by a sequence of events that results from the altered status of the endothelium. The second major step in the process of reperfusion injury is the "neutrophil amplification step," which involves leukocyte-endothelial cell interactions leading to leukocyte adherence to the endothelium and transendothelial migration of neutrophils across the endothelium. 5 There is a dramatic increase in neutrophil adherence, which reaches its maximum at 20 minutes postreperfusion. 6 These data strongly implicate the role of adhesion molecule expression and especially of P-selectin, which are up-regulated within a few minutes. 7 This enhanced leukocyte adherence to the endothelium leads to capillary plugging and edema formation, resulting in reduction of coronary blood flow. The response to ischemiareperfusion injury is termed the "no-reflow phenomenon." 8 These events culminate in a profound degree of myocardial cell necrosis and/or apoptosis at 4 to 24 hours postreperfusion, with early and late reduction of myocardial contractility. 9 Because reduced NO release is proven to be a marked and early event in the reperfusion injury, we speculated that NO replacement therapy could blunt the consequences of ischemia-reperfusion injury. One component of the reduced NO release is the enhanced quenching of NO by superoxide radicals, which appears to be related to superoxide radicals produced by the abrupt reoxygenation of the reperfusion process. 10 The present investigation addresses the beneficial effect of inhaled NO, administered at pharmacological dosages (20 ppm) during and for 8 hours after CPB, in minimizing the release of markers of myocardial injury and left ventricular dysfunction in patients undergoing CPB.
Methods

Study Design
This investigation was designed as a prospective, randomized, nonblinded study carried out at the Pasquinucci Hospital in Massa, Italy, between July 2000 and April 2002. After approval of the Local Ethical Commission, informed consent was obtained from 29 patients undergoing nonemergency aortic valve replacement combined with aortocoronary bypass, and the patients were enrolled in the present study.
Patients with an active infection, ejection fraction Ͻ30%, malignancy, or a history of hematologic, hepatic, or renal disorders were excluded. Exclusion criteria also included corticosteroid or a nonsteroidal anti-inflammatory treatment within the previous 7 days or during surgery, or a postoperative treatment with nitrates or sodium nitroprussiate.
Study Procedures
All potential patients were screened before enrollment. When all inclusion and exclusion criteria were satisfied, patients were randomized. Perioperative testing included medical history and physical examination, laboratory testing (hematology, chemistry, and urinalysis), electrocardiogram, and echocardiography. Demographic characteristics and surgical data are reported in Table 1 .
Surgical Protocol
The surgical protocol consisted of conventional median sternotomy access and the institution of CPB using a double-stage venous cannula in the right atrium and an arterial cannula in the ascending aorta. All procedures were performed in mild hypothermia (32-35°C), using retrograde, intermittent, hematic hyperkalemic cardioplegic solution through the coronary sinus.
NO Delivery, Systems, and Timing NO gas was mixed with nitrogen (500 ppm). The mixture of gases was continuously introduced into the patient's ventilatory circuit and was connected to a time-cycled anesthesia machine ventilator (Servo 900D; Siemens-Elema, Stockholm, Sweden). The NO gas inlet was proximally connected to the inspiratory part of the patient ventilatory circuit. The concentration of NO delivered was sidestream analyzed by a chemiluminescent instrument (Nox Box Bedfont Scientific, Kent, United Kingdom) connected to the distal inspiratory limb of the ventilatory circuit. The exhaled gas and gases exiting the chemiluminescence instrument were collected into a Venturi device (Servo 900D; Siemens-Elema, Stockholm, Sweden) and discharged into the hospital vacuum system. At the onset of CPB (when 100% oxygen is usually delivered to the membrane oxygenator), NO was delivered to the oxygenator with our hospital's standardized oxygen/air mixture flow into the side port of the inlet gas tubing, close to the flowmeters. The cardioplegic solution circuit was designed to administer oxygenated hyperkalemic blood enriched with NO. The NO analyzing instrument was connected at the distal part of the gas tubing, close to the oxygenator. The delivery of NO was adjusted using a flowmeter on the cylinder manifold to provide a constant preset concentration of NO. The fine-tuning of the NO concentration delivered was corrected on the basis of the chemiluminescent analysis. The NO was administered to each patient during the entire period of intubation, from the operating theater to the intensive care unit. In particular, NO delivery was started immediately after patient intubation in the operating theater via the ventilatory circuit, then continued throughout the CPB directly into the pump prime and in the intensive care unit via the ventilator circuits until suspension of mechanical ventilation. The gas outflow from the membrane oxygenator was scavenged using the wall-mounted vacuum system. During inhalation, hemodynamic variables were monitored by routine cardiac catheterization. A standard blood gas analyzer was used to measure PaO 2 , PaCO 2 , and pH.
Blood Sample Collection
Blood samples for indices of myocardial injury were drawn before surgery and 4, 12, 24, and 48 hours after surgery. NO by-products were measured in blood samples taken prethoracotomy (before heparinization), 5 minutes post-aortic clamping, 5 minutes postaortic unclamping, and 24 hours postsurgery, approximately 12 hours after NO was stopped. Analogously, for brain natriuretic peptide (BNP) measurements we used peripheral blood samples drawn prethoracotomy (before heparinization), 5 minutes postaortic clamping, 5 minutes post-aortic unclamping, 5 minutes post-CPB, and 4 and 24 hours postsurgery. Blood samples from coronary sinus were taken before and after cardioplegia for Pselectin measurements. All samples were immediately centrifuged at 4°C and stored at Ϫ80°C until they were assayed.
Biological Assays
Soluble P-selectin was measured by a double sandwich enzymelinked immunosorbent assay (Bender, Vienna, Austria) in heparinized plasma samples. 11 Assays were performed in duplicate on duplicate samples, each assayed at least at 2 different dilutions. Values obtained in healthy people ranged between 100 and 300 ng/mL, in accordance with the literature.
11 Plasma BNP was measured by a noncompetitive immunofluorometric assay (Triage BNP Test, Biosite Diagnostics, Inc, San Diego, Calif), as described elsewhere. 12 The imprecision of the Triage method was about 12% for BNP concentrations in the normal range and about 18% for BNP concentrations above the normal range. The working range was 5 to 1300 pg/mL.
Measurements of NO Metabolites
To analyze the NO metabolites (NOx), the plasma samples were ultrafiltered through 30-KDa molecular weight cutoff filters and centrifuged at 1000g for 60 minutes to remove hemoglobin, which is known to interfere with subsequent spectrophotometric measurements. Afterward, NOx concentration was determined by a colorimetric assay kit (Cayman, Ann Arbor, Mich) based on Griess reaction. 13 Standards for calibration curves were prepared with nitrate and taken through the full assay procedure. The results were expressed as mol/L of NOx.
Creatine Kinase-MB and Troponin I Assay
Myocardial-specific isoforms of creatine kinase (CK) and troponin I were measured in our clinical laboratory by a point-of-care immunometric technique (Triage cardiac panel kit).
Statistical Analysis
All data are presented as mean Ϯ standard error of the mean (SEM). Statistical analysis was performed by multivariate analysis of variance for repeated measurements for a comparison among more than 2 groups and Student t test for a comparison between 2 groups; correlation among variables was estimated by a linear regression analysis with the aid of the Statview statistical package (Abacus Concepts, Inc, Berkeley, Calif).
Results
Population Characteristics
Demographic variables, chemistry laboratory values, and surgical parameters (Table 1) did not significantly differ between the 2 patient groups.
NO By-product Measurements
Measurements of NO metabolites showed significant intraand intergroup differences: in the NO group the peak level was observed at time T1, corresponding to the intraoperatory sample, before thoracotomy, 10 minutes after starting NO inhalation (Figure 1 ). NO metabolites continued to exhibit significantly higher levels compared with basal val- ues (P ϭ .02) at 5 minutes post-aortic clamping (T2) and 5 minutes post-aortic unclamping (T3), corresponding to the extracorporeal circulation period, when NO was administered in the membrane oxygenator as described. At time T4, 24 hours after surgery and about 12 hours after stopping NO inhalation, NO by-products completely reverted to basal levels. In the control group we did not observe a significant increase in NO by-products during the extracorporeal circulation period compared with basal values. Overall comparison between NO and control groups indicated a statistically significant difference (P ϭ .01).
Analysis of Myocardial Injury
Indices of myocardial injury showed a constant increase throughout the first 24 hours after surgery (Figure 2 ). Comparison between groups for total CK release indicated a statistically significant difference at 24 and 48 hours (P ϭ .02; Figure 2 , A) and for the cumulative release summarized by the area under the curve (AUC; P ϭ .04; Figure 2, B) . Analogously, we found the peak levels of creatine kinase MB fraction (CK-MB) at 24 hours (P ϭ .01); values at 48 hours (P ϭ .01; Figure 2 , C) and the AUC (P ϭ .03; Figure  2 , D) were significantly lower in the NO group as compared with the control group. Moreover, in the same group the AUC of troponin I was lower than in the control group (P ϭ .04; Figure 3 ).
Analysis of Endothelial Cell Activation
In both groups we observed a relevant increase of soluble P-selectin in plasma samples collected from coronary sinus immediately before and after aortic clamping (Figure 4, A) . The amount of this inflammatory release, which was also calculated as a pre-/post-aortic clampage gradient ( Figure  4, B) , turned out to be significantly blunted in the NO group as compared with the control group (P ϭ .02).
Analysis of Left Ventricular Dysfunction
To normalize the basal values (T1), we analyzed the gradient of BNP release as measured by the percent of the ratio between the levels at each time (T2-T6) compared with T1 ( Figure 5 ). We observed a statistically significant difference at T5 (P ϭ .02), with lower levels (249 Ϯ 71 vs 311 Ϯ 141 pg/mL) in the NO group.
Discussion
Effective inhibition of CPB-induced inflammatory reaction and of ischemia-reperfusion injury following coronary artery bypass surgery has the potential to significantly reduce clinical morbidity.
14 These phenomena are both present in patients undergoing aortic valve replacement and coronary artery bypass revascularization.
We report that administration of NO via inhalation immediately before, during, and after surgery may positively 
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affect the pattern of release of markers of myocardial injury and left ventricular dysfunction, independently on its hemodynamic effects on the pulmonary vasculature and arterial saturation.
A major pathophysiological clue of the post-CPB reaction is an overall decrease of the endothelial NO synthase, responsible for a deficient vasodilatory tendency of the microvasculature and for an increased permeability of the endothelium toward circulating leukocytes. 15 As a consequence, an inflammatory infiltration spreads out inside peripheral tissues, releasing toxic mediators that further amplify the inflammatory reaction and cause organ injury. 16 In this context, restoring NO production is theoretically beneficial. NO inhalation is an alternative route of administration of NO, with peculiarities that can account for specific advantages versus other approaches. NO easily diffuses through the air-blood barrier into the pulmonary circulation. NO inhalation in a low dosage causes selective pulmonary vasodilation. 17 In this district NO diffuses into the smooth muscle cells, increasing cyclic guanylate monophosphate (cGMP) concentrations, whereas it does not cause systemic hypotension, being quickly inactivated by avid binding to hemoglobin. 18 In addition to these proper- ties, inhaled NO can mediate some anti-inflammatory effects directly on the circulating leukocytes and platelets. In fact, NO gas inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. 19 If the concentration of inhaled NO in the inspiratory gas is below 80 ppm we do not expect pro-oxidant effects. 20 Interestingly, NO donors have variable rates of NO release and some of these substances release different molecules, with potential collateral effects. 21 By measuring NO by-products in peripheral plasma samples we were able to document a significant increase during NO therapy beginning with the ventilatory phase and continuing throughout the extracorporeal circulation (T2 and T3), although at a lower rate. As we measured peak levels at time T1, just 10 to 15 minutes after starting inhalation, we confirmed the fast action of inhaled NO provided by this route of administration. Lower levels at T2 and T3 as compared with T1 indicated a less efficient diffusion of NO through the membrane oxygenator as compared with its diffusion across the alveolar-blood barrier. Whether the NO blood concentrations during this phase were adequate or not is a matter needing further investigation; neither is there a clear-cut idea about the possible correlation between NO by-products levels and clinical outcome.
At 20 ppm of inhaled NO we failed to observe any effects on peripheral vascular resistance, whereas the pulmonary vascular resistance was significantly decreased, as expected (75 Ϯ 8 vs 125 Ϯ 16 dynes · s/cm Ϫ5 , P ϭ .002). Moreover, NO and control groups showed comparable results in term of arterial oxygen saturation and arterial tension of oxygen, time of intubation, time in intensive care unit, and postoperative ejection fraction (data not shown). Even in a relatively small number of patients we report a significant protection against perioperative release of markers of myocardial injury, as indicated by the overall reduced amounts of total CK, CK-MB, and troponin I levels throughout the first 24 hours after surgery. This effect was more impressive in patients with a lower release of soluble P-selectin in the coronary sinus, measured by the pre-/ postcardioplegia gradient, as shown by the correlation between the total amount of CK-MB release and the soluble P-selectin gradient in the local circulation ( Figure 6 ).
This observation, even if it cannot be interpreted as a definitive explanation of the NO biological action, may suggest the hypothesis that NO supplementation in the local circulation, by providing NO directly in the cardioplegic solution, has a significant anti-inflammatory effect, per se, cardioprotective.
This finding is just a preliminary report suggesting a potential therapeutic effect of supplemental NO administered before, during, and after CPB. Already some evidence of the beneficial properties of inhaled NO on ischemiareperfusion injury are available in animal models. In 1996 in a canine model of platelet-mediated reocclusion after thrombolysis, inhaled NO improved the coronary artery patency rate. 22 Moreover, the observation in the NO group of lower levels of BNP release, a surrogate of early left ventricular dysfunction as recently suggested by the European Task Force for the Diagnosis and Treatment of Heart Failure 24 ( Figure 5 ), supports the hypothesis of a real cardioprotective effect of the NO supplementation. Because the cardioplegic circuit was designed to administer oxygenated hyperkalemic blood enriched with NO, thus delivering the same amount of NO as the peripheral blood circulating in the extracorporeal circuit, this method of administration may be the best access route of therapeutic NO. In fact, whereas the pulmonary inhaled NO is almost completely metabolized before reaching the left atrium, NO supplemented in the cardioplegic solution directly diffuses in the coronary circulation and may elicit a local therapeutic effect.
Limitations of the Study
Several points regarding the effect of supplemented NO are lacking and need further investigation, such as the optimal duration of NO treatment, a dose titration of inhaled NO, a time course of NO by-products to establish how long-lasting the effect is, and how soon after stopping NO inhalation the rate of NO by-products falls.
Moreover, the inclusion of patients with combined coronary artery disease could actually add a confounding variable in our analysis; however, major surgical parameters in the 2 randomized groups were equivalent, including coronary artery disease, the time of CPB, and the time of aortic clamping (Table 1) . Finally, our study had a short followup, limited to the in-hospital period, and was lacking of major clinical end points that could support the cardioprotective effect of NO. This work is just a pilot and observational study, based on data of biochemical markers of myocardial injury and left ventricular dysfunction, and requires confirmation by a larger interventional study to verify the opportunity to extend the use of NO in clinical settings involving ischemia-reperfusion damage.
